Provectus Biopharmaceuticals (PVCT) announced that it has formed an Australian subsidiary, Provectus Biopharmaceuticals Australia Pty Ltd. that included opening a Sydney office in New South Wales. Interim CEO Peter Culpepper said that the reation of an Australian entity is a fundamental part of company's plans for extended global reach in conjunction with planned partnering for commercialization of PV-10. The new unit should make it easier to work with Australian regulatory authorities and having an office in the region may facilitate our work in Asian markets as Sydney is just two hours ahead of Beijing, Hong Kong and Singapore.